Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Regis Healthcare Ltd
ABN	11 125 203 054

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Linda Jane Mellors
Date of last notice	16 October 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct							
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Performance rights granted to Dr Mellors by the Company pursuant to the 2024 long term incentive (LTI) plan approved at the Annual General Meeting held on 24 October 2023 (AGM) and subject to performance conditions measured over the 3-year performance period. Upon vesting, each Right may be exercised and converted to one fully paid ordinary share in the Company. The Board retains a discretion to make a cash equivalent payment instead of an allocation of shares.							
Date of change	20 December 2023							
No. of securities held prior to change	213,235 Ordinary shares 535,301 Rights (unquoted)							
Class	Rights (unquoted)							
Number acquired	333,838 performance rights (unquoted)							
Number disposed	N/A							

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	No cash consideration is payable. 333,838 performance rights issued under the 2024 LTI plan
No. of securities held after change	213,235 Ordinary shares 869,139 Rights (unquoted)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Performance Rights granted to Dr Mellors by the Company pursuant to the 2024 LTI plan approved at the AGM (subject to performance conditions measured over the 3-year performance period).

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder	
(if issued securities)	
Date of change	
No. and class of securities to which	
interest related prior to change	
Note: Details are only required for a	
contract in relation to which the	
interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration	
Note: If consideration is non-cash,	
provide details and an estimated	
valuation	
Interest after change	

Part 3 - +Closed period

Were the interests in the securities or contracts detailed above traded during a *closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Appendix 3Y Change of Director's Interest Notice

If prior writ	ten clearance	was n	rovided	٥n	what	date	was	this
ii piioi wiit	ten olearanoe	was p	noviaca,	011	wiiat	uuto	mus	11113
provided?								
providou								

⁺ See chapter 19 for defined terms.